New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:37 EDTBIOCBiocept expands breast cancer offering
Biocept announced the launch of its estrogen receptor status testing on CTCs that will be performed at the Company's CLIA-certified and CAP-accredited laboratory. The launch of ER status testing, in conjunction with the company's HER2 receptor status test, will offer health care providers an additional testing option when a tumor biopsy is unavailable or unsafe. For patients with recurring or newly diagnosed metastatic breast cancer, accurate identification of hormone and HER2 receptors status plays a major role in treatment outcomes. The company said, "Our validation study for hormone status provided significant insights into hormone status as it relates to primary and metastatic breast cancers. We were able to correlate both concordance and discordance of primary biopsy tissue and metastatic biopsy tissue with the CTC status of estrogen receptors."
News For BIOC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
08:48 EDTBIOCBiocept launches ROS1 testing on CTCs
Biocept announced the launch of ROS1 testing on CTCs, which will help physicians identify which of their patients may be receptive to certain drugs for the treatment of non-small cell lung cancer. Biocept's new blood test identifies chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase, or ROS1, thereby defining a distinct molecular subgroup of NSCLCs. Patients with ROS1-positive tumors may be receptive to a number of therapeutic options that inhibit this target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use